The Experts below are selected from a list of 10746 Experts worldwide ranked by ideXlab platform
Keduo Qian - One of the best experts on this subject based on the ideXlab platform.
-
anti aids agents 90 novel c 28 modified bevirimat analogues as potent hiv Maturation Inhibitors
Journal of Medicinal Chemistry, 2012Co-Authors: Keduo Qian, Kuo Hsiung Lee, Chin Ho Chen, Li Huang, Ibrahim D BoriAbstract:In a continuing study of bevirimat (2), the anti-HIV-Maturation clinical trials agent, 28 new betulinic acid (BA, 1) derivatives were designed and synthesized. Among these compounds, 17, with a C-28 MEM ester moiety, and 22, with a C-28 ethyl hexanoate, increased the anti-HIV replication activity compared with 2 by 2-fold while compounds 40, 41, 48, and 49, with C-28 piperazine or piperidine amide substitutions, increased the activity by 3- to 15-fold. The best new compound, 41, exhibited an anti-HIV IC50 of 0.0059 μM compared with 0.087 μM for 2. All of the active compounds showed only antiMaturation effects, as confirmed by TZM-bl assay, in blocking the HIV replication. The results suggest that proper C-28 substitutions can further enhance the antiMaturation activity of 2 without any antientry effects. Thus, 41 may serve as a promising new lead for development of anti-AIDS clinical trial candidates.
-
anti aids agents 88 anti hiv conjugates of betulin and betulinic acid with azt prepared via click chemistry
Tetrahedron Letters, 2012Co-Authors: Ibrahim D Bori, Chin Ho Chen, Keduo Qian, Hsin Yi Hung, Susan L MorrisnatschkeAbstract:Due to the expanded and improved HIV programs, the number of new global HIV infections declined 19% over the past decade. However, this progress is fragile and unevenly distributed. HIV incidence is still increasing in some countries and regions, and too many new infections are occurring, 2.6 million in 2009 alone, contributing to the current global incidence of 33.3 million.1 New infections continue to outpace the number of people placed on treatment, and the efficacy of the treatments is hampered by the emergence of drug-resistant viral strains and severe drug-drug interactions. Therefore, novel potent antiretroviral agents with different targets and acceptable prices are still urgently needed. Two lupine-type triterpenes betulin and betulinic acid (BA), which are readily available from the birch tree in large quantity, exhibit diverse pharmacological activities, including anti-HIV, anti-cancer, and anti-inflammatory activities.2 Among the BA/betulin derivatives, bevirimat [3-O-(3′,3′-dimethylsuccinyl)betulinic acid, 14] was found to exhibit remarkable anti-HIV-1 activity against primary and drug-resistant HIV-1 isolates,3, 4 representing a unique first in a class of anti-HIV compounds termed Maturation Inhibitors (MIs).4, 5 Bevirimat has recently succeeded in Phase IIb clinical trials.6–9 In our prior study, AZT (3′-azido-3′-deoxythymidine), a clinically used nucleoside reverse transcriptase inhibitor (NRTI), was conjugated with 3-O-(3′,3′-dimethylsuccinyl)betulin at its C-28 position using different linkers. The goal was to provide multi-target therapeutics in one molecule in order to reduce the risk of drug-drug interaction, which can occur from mixing monotherapies,.10 The conjugates were formed via an ester bond, which was meant to subsequently be hydrolyzed inside the cells and release two different chemical entities exerting two pharmacological functions, anti-Maturation and anti-reverse transcriptase. However, one potential drawback of this design is that the hydroxyl group of AZT, which needs to undergo phosphorylation inside host cells to become active, forms the linker bond with the betulin derivatives. Consequently, the inhibitory ability of AZT is highly dependent on the ability of the conjugate to dissociate. In order to improve this issue, we investigated another strategy to link AZT with betulin and BA via the azido group of AZT by using click chemistry. Click chemistry as introduced by K. Barry Sharpless is a chemical philosophy to mimic nature’s ability to make carbon-heteroatom bonds rather than carbon-carbon bonds.11 Conjugation of AZT with betulin and BA by this methodology has the following potential benefits. 1) Click chemistry is designed to link the azido group of AZT with an alkyne group on betulin/BA derivatives, leaving the hydroxyl group of AZT free to be phosphorylated. 2) The linking triazole group is physiologically stable in cells. Thus, the new conjugated molecule will not be degraded inside the cells, which should reduce the potential drug-drug interactions. 3) In addition, the triazole linkage formed by click chemistry may also offer extra interaction with virus proteins. Based on this rationale, the present study reports the synthesis and anti-HIV activity of the newly designed AZT-betulin and AZT-BA conjugates. The synthetic route to compounds conjugated at the C-3 position of betulin is outlined in Scheme 1. The C-28 hydroxyl of betulin was first protected by reaction with tert-butyldimethylsilyl chloride (TBSCl) to yield the silyl ether 1. Prop-2-ynyl groups were then introduced at the C-3 position as either an ether (2) or carbonate ester (3). Compounds 2 and 3 were then reacted with the azido group of AZT in the presence of Cu and CuSO4·5H2O to furnish final compounds 8 and 9 in quantitative yields. Analogous final compounds 10 and 11 were obtained by the same click reaction of AZT with the C-28 de-protected betulin derivatives 4 and 5. Oxidation of the C-28 hydroxyl of 4 with Jones reagent yielded 6, which was also reacted with AZT to yield 12, an AZT-BA conjugate. Finally, a 3′,3′-dimethylsuccinyl ester was introduced at the C-28 position of 4 to yield compound 7, which was converted by click chemistry to the conjugate 13. Scheme 2 depicts the synthesis of AZT-bevirimat conjugates. A prop-2-ynyl ester moiety was added to the C-28 position of bevirimat (14) to furnish 15, followed by click reaction of 15 with AZT to yield final compound 16. Compared with the previous yields (42.7–87.3%) for conjugating AZT with betulin derivatives via an ester bond,10 the click reactions of AZT with betulin/BA derivatives were achieved quantitatively, which is a significant advantage in the last step of synthesizing the target compounds. In addition, the reaction time was shortened significantly to 30 min by using microwave conditions at 120 °C (followed by dilution with EtOAc, washing with NaHCO3 and brine, and chromatography), rather than the prior overnight esterification reaction. Therefore, the click reaction provides a much more productive and rapid approach to obtain the final products of AZT-betulin/BA conjugates. Scheme 1 AZT conjugation at C-3 position Scheme 2 AZT conjugation at C-28 position The anti-HIV activity data of all new compounds are summarized in Table 1. Among the tested compounds, conjugates 8 and 13 with AZT linked through the C-3 side chain of betulin/BA showed moderate antiviral activity with EC50 values of 0.19 and 0.35 µM, respectively. The C-3 ether bond (8) was favored for activity compared with the C-3 carbonate ester bond (corresponding conjugate 9 was inactive). Conjugates with a free C-28 hydroxyl (10 and 11) or carboxylic acid group (12) showed no inhibitory activity, compared with conjugates with a C-28 TBS ether (8) or dimethylsuccinyl ester (13). Between the two active conjugates, the smaller C-28 TBS side chain in 8 was favored compared with the longer dimethylsuccinyl side chain in 13. Overall, in this limited data set, when AZT and betulin/BA are conjugated at the C-3 position, a shorter distance between AZT-betulin/BA and the presence of a small extra side chain at C-28 are important for the conjugates’ antiviral activity. Table 1 Anti-HIV data against HIV-1NL4–3 infected MT-4 cells. The non-conjugated 15 with a 3-O-3′,3′-dimethylsuccinyl side chain at C-3 and propynyl ester moiety at C-28 showed potent anti-HIV activity with an EC50 of 0.067 µM and a selectivity index (SI, ratio of cytotoxic/anti-viral activity) of 226. The AZT-bevirimat conjugate 16 also exhibited anti-HIV activity with an EC50 of 0.10 µM and a SI of 101. Thus, these two compounds and AZT (EC50: 0.10 µM) showed comparable activity in our assay system. As a pioneer compound, conjugate 16 demonstrates that a click reaction can be used easily with a large natural product (e.g. BA), which contains a terminal alkyne moiety, to form conjugates. The potent anti-HIV activity of compounds 15 and 16 proves that the incorporation of a C-28 side chain in bevirimat may result in retained or even increased antiviral activity. We are currently investigating synthesis and antiviral evaluation of additional AZT-bevirimat conjugates with different sizes/lengths of linkers between the C-28 carboxylic acid and the triazole moiety formed by click reaction with AZT. In conclusion, conjugation via triazole linkage offers a new direction of modification of anti-HIV triterpenes. Click chemistry provides an easy and productive way for linking two molecules, even when one of them is a large natural product. Preliminary results indicated that AZT-betulin/BA conjugates with proper substitutions at the C-3 and C-28 positions showed potent antiviral activity comparable to bevirimat and AZT. Mechanistic studies are currently ongoing.
-
anti aids agents 81 design synthesis and structure activity relationship study of betulinic acid and moronic acid derivatives as potent hiv Maturation Inhibitors
Journal of Medicinal Chemistry, 2010Co-Authors: Keduo Qian, Chin Ho Chen, Li Huang, Susan L MorrisnatschkeAbstract:In our continuing study of triterpene derivatives as potent anti-HIV agents, different C-3 conformationally restricted betulinic acid (BA, 1) derivatives were designed and synthesized in order to explore the conformational space of the C-3 pharmacophore. 3-O-Monomethylsuccinyl-betulinic acid (MSB) analogues were also designed to better understand the contribution of the C-3′ dimethyl group of bevirimat (2), the first-in-class HIV Maturation inhibitor, which is currently in phase IIb clinical trials. In addition, another triterpene skeleton, moronic acid (MA, 3), was also employed to study the influence of the backbone and the C-3 modification toward the anti-HIV activity of this compound class. This study enabled us to better understand the structure−activity relationships (SAR) of triterpene-derived anti-HIV agents and led to the design and synthesis of compound 12 (EC50: 0.0006 μM), which displayed slightly better activity than 2 as a HIV-1 Maturation inhibitor.
Kuo Hsiung Lee - One of the best experts on this subject based on the ideXlab platform.
-
anti aids agents 90 novel c 28 modified bevirimat analogues as potent hiv Maturation Inhibitors
Journal of Medicinal Chemistry, 2012Co-Authors: Keduo Qian, Kuo Hsiung Lee, Chin Ho Chen, Li Huang, Ibrahim D BoriAbstract:In a continuing study of bevirimat (2), the anti-HIV-Maturation clinical trials agent, 28 new betulinic acid (BA, 1) derivatives were designed and synthesized. Among these compounds, 17, with a C-28 MEM ester moiety, and 22, with a C-28 ethyl hexanoate, increased the anti-HIV replication activity compared with 2 by 2-fold while compounds 40, 41, 48, and 49, with C-28 piperazine or piperidine amide substitutions, increased the activity by 3- to 15-fold. The best new compound, 41, exhibited an anti-HIV IC50 of 0.0059 μM compared with 0.087 μM for 2. All of the active compounds showed only antiMaturation effects, as confirmed by TZM-bl assay, in blocking the HIV replication. The results suggest that proper C-28 substitutions can further enhance the antiMaturation activity of 2 without any antientry effects. Thus, 41 may serve as a promising new lead for development of anti-AIDS clinical trial candidates.
Susan L Morrisnatschke - One of the best experts on this subject based on the ideXlab platform.
-
anti aids agents 88 anti hiv conjugates of betulin and betulinic acid with azt prepared via click chemistry
Tetrahedron Letters, 2012Co-Authors: Ibrahim D Bori, Chin Ho Chen, Keduo Qian, Hsin Yi Hung, Susan L MorrisnatschkeAbstract:Due to the expanded and improved HIV programs, the number of new global HIV infections declined 19% over the past decade. However, this progress is fragile and unevenly distributed. HIV incidence is still increasing in some countries and regions, and too many new infections are occurring, 2.6 million in 2009 alone, contributing to the current global incidence of 33.3 million.1 New infections continue to outpace the number of people placed on treatment, and the efficacy of the treatments is hampered by the emergence of drug-resistant viral strains and severe drug-drug interactions. Therefore, novel potent antiretroviral agents with different targets and acceptable prices are still urgently needed. Two lupine-type triterpenes betulin and betulinic acid (BA), which are readily available from the birch tree in large quantity, exhibit diverse pharmacological activities, including anti-HIV, anti-cancer, and anti-inflammatory activities.2 Among the BA/betulin derivatives, bevirimat [3-O-(3′,3′-dimethylsuccinyl)betulinic acid, 14] was found to exhibit remarkable anti-HIV-1 activity against primary and drug-resistant HIV-1 isolates,3, 4 representing a unique first in a class of anti-HIV compounds termed Maturation Inhibitors (MIs).4, 5 Bevirimat has recently succeeded in Phase IIb clinical trials.6–9 In our prior study, AZT (3′-azido-3′-deoxythymidine), a clinically used nucleoside reverse transcriptase inhibitor (NRTI), was conjugated with 3-O-(3′,3′-dimethylsuccinyl)betulin at its C-28 position using different linkers. The goal was to provide multi-target therapeutics in one molecule in order to reduce the risk of drug-drug interaction, which can occur from mixing monotherapies,.10 The conjugates were formed via an ester bond, which was meant to subsequently be hydrolyzed inside the cells and release two different chemical entities exerting two pharmacological functions, anti-Maturation and anti-reverse transcriptase. However, one potential drawback of this design is that the hydroxyl group of AZT, which needs to undergo phosphorylation inside host cells to become active, forms the linker bond with the betulin derivatives. Consequently, the inhibitory ability of AZT is highly dependent on the ability of the conjugate to dissociate. In order to improve this issue, we investigated another strategy to link AZT with betulin and BA via the azido group of AZT by using click chemistry. Click chemistry as introduced by K. Barry Sharpless is a chemical philosophy to mimic nature’s ability to make carbon-heteroatom bonds rather than carbon-carbon bonds.11 Conjugation of AZT with betulin and BA by this methodology has the following potential benefits. 1) Click chemistry is designed to link the azido group of AZT with an alkyne group on betulin/BA derivatives, leaving the hydroxyl group of AZT free to be phosphorylated. 2) The linking triazole group is physiologically stable in cells. Thus, the new conjugated molecule will not be degraded inside the cells, which should reduce the potential drug-drug interactions. 3) In addition, the triazole linkage formed by click chemistry may also offer extra interaction with virus proteins. Based on this rationale, the present study reports the synthesis and anti-HIV activity of the newly designed AZT-betulin and AZT-BA conjugates. The synthetic route to compounds conjugated at the C-3 position of betulin is outlined in Scheme 1. The C-28 hydroxyl of betulin was first protected by reaction with tert-butyldimethylsilyl chloride (TBSCl) to yield the silyl ether 1. Prop-2-ynyl groups were then introduced at the C-3 position as either an ether (2) or carbonate ester (3). Compounds 2 and 3 were then reacted with the azido group of AZT in the presence of Cu and CuSO4·5H2O to furnish final compounds 8 and 9 in quantitative yields. Analogous final compounds 10 and 11 were obtained by the same click reaction of AZT with the C-28 de-protected betulin derivatives 4 and 5. Oxidation of the C-28 hydroxyl of 4 with Jones reagent yielded 6, which was also reacted with AZT to yield 12, an AZT-BA conjugate. Finally, a 3′,3′-dimethylsuccinyl ester was introduced at the C-28 position of 4 to yield compound 7, which was converted by click chemistry to the conjugate 13. Scheme 2 depicts the synthesis of AZT-bevirimat conjugates. A prop-2-ynyl ester moiety was added to the C-28 position of bevirimat (14) to furnish 15, followed by click reaction of 15 with AZT to yield final compound 16. Compared with the previous yields (42.7–87.3%) for conjugating AZT with betulin derivatives via an ester bond,10 the click reactions of AZT with betulin/BA derivatives were achieved quantitatively, which is a significant advantage in the last step of synthesizing the target compounds. In addition, the reaction time was shortened significantly to 30 min by using microwave conditions at 120 °C (followed by dilution with EtOAc, washing with NaHCO3 and brine, and chromatography), rather than the prior overnight esterification reaction. Therefore, the click reaction provides a much more productive and rapid approach to obtain the final products of AZT-betulin/BA conjugates. Scheme 1 AZT conjugation at C-3 position Scheme 2 AZT conjugation at C-28 position The anti-HIV activity data of all new compounds are summarized in Table 1. Among the tested compounds, conjugates 8 and 13 with AZT linked through the C-3 side chain of betulin/BA showed moderate antiviral activity with EC50 values of 0.19 and 0.35 µM, respectively. The C-3 ether bond (8) was favored for activity compared with the C-3 carbonate ester bond (corresponding conjugate 9 was inactive). Conjugates with a free C-28 hydroxyl (10 and 11) or carboxylic acid group (12) showed no inhibitory activity, compared with conjugates with a C-28 TBS ether (8) or dimethylsuccinyl ester (13). Between the two active conjugates, the smaller C-28 TBS side chain in 8 was favored compared with the longer dimethylsuccinyl side chain in 13. Overall, in this limited data set, when AZT and betulin/BA are conjugated at the C-3 position, a shorter distance between AZT-betulin/BA and the presence of a small extra side chain at C-28 are important for the conjugates’ antiviral activity. Table 1 Anti-HIV data against HIV-1NL4–3 infected MT-4 cells. The non-conjugated 15 with a 3-O-3′,3′-dimethylsuccinyl side chain at C-3 and propynyl ester moiety at C-28 showed potent anti-HIV activity with an EC50 of 0.067 µM and a selectivity index (SI, ratio of cytotoxic/anti-viral activity) of 226. The AZT-bevirimat conjugate 16 also exhibited anti-HIV activity with an EC50 of 0.10 µM and a SI of 101. Thus, these two compounds and AZT (EC50: 0.10 µM) showed comparable activity in our assay system. As a pioneer compound, conjugate 16 demonstrates that a click reaction can be used easily with a large natural product (e.g. BA), which contains a terminal alkyne moiety, to form conjugates. The potent anti-HIV activity of compounds 15 and 16 proves that the incorporation of a C-28 side chain in bevirimat may result in retained or even increased antiviral activity. We are currently investigating synthesis and antiviral evaluation of additional AZT-bevirimat conjugates with different sizes/lengths of linkers between the C-28 carboxylic acid and the triazole moiety formed by click reaction with AZT. In conclusion, conjugation via triazole linkage offers a new direction of modification of anti-HIV triterpenes. Click chemistry provides an easy and productive way for linking two molecules, even when one of them is a large natural product. Preliminary results indicated that AZT-betulin/BA conjugates with proper substitutions at the C-3 and C-28 positions showed potent antiviral activity comparable to bevirimat and AZT. Mechanistic studies are currently ongoing.
-
anti aids agents 81 design synthesis and structure activity relationship study of betulinic acid and moronic acid derivatives as potent hiv Maturation Inhibitors
Journal of Medicinal Chemistry, 2010Co-Authors: Keduo Qian, Chin Ho Chen, Li Huang, Susan L MorrisnatschkeAbstract:In our continuing study of triterpene derivatives as potent anti-HIV agents, different C-3 conformationally restricted betulinic acid (BA, 1) derivatives were designed and synthesized in order to explore the conformational space of the C-3 pharmacophore. 3-O-Monomethylsuccinyl-betulinic acid (MSB) analogues were also designed to better understand the contribution of the C-3′ dimethyl group of bevirimat (2), the first-in-class HIV Maturation inhibitor, which is currently in phase IIb clinical trials. In addition, another triterpene skeleton, moronic acid (MA, 3), was also employed to study the influence of the backbone and the C-3 modification toward the anti-HIV activity of this compound class. This study enabled us to better understand the structure−activity relationships (SAR) of triterpene-derived anti-HIV agents and led to the design and synthesis of compound 12 (EC50: 0.0006 μM), which displayed slightly better activity than 2 as a HIV-1 Maturation inhibitor.
Chin Ho Chen - One of the best experts on this subject based on the ideXlab platform.
-
anti aids agents 90 novel c 28 modified bevirimat analogues as potent hiv Maturation Inhibitors
Journal of Medicinal Chemistry, 2012Co-Authors: Keduo Qian, Kuo Hsiung Lee, Chin Ho Chen, Li Huang, Ibrahim D BoriAbstract:In a continuing study of bevirimat (2), the anti-HIV-Maturation clinical trials agent, 28 new betulinic acid (BA, 1) derivatives were designed and synthesized. Among these compounds, 17, with a C-28 MEM ester moiety, and 22, with a C-28 ethyl hexanoate, increased the anti-HIV replication activity compared with 2 by 2-fold while compounds 40, 41, 48, and 49, with C-28 piperazine or piperidine amide substitutions, increased the activity by 3- to 15-fold. The best new compound, 41, exhibited an anti-HIV IC50 of 0.0059 μM compared with 0.087 μM for 2. All of the active compounds showed only antiMaturation effects, as confirmed by TZM-bl assay, in blocking the HIV replication. The results suggest that proper C-28 substitutions can further enhance the antiMaturation activity of 2 without any antientry effects. Thus, 41 may serve as a promising new lead for development of anti-AIDS clinical trial candidates.
-
anti aids agents 88 anti hiv conjugates of betulin and betulinic acid with azt prepared via click chemistry
Tetrahedron Letters, 2012Co-Authors: Ibrahim D Bori, Chin Ho Chen, Keduo Qian, Hsin Yi Hung, Susan L MorrisnatschkeAbstract:Due to the expanded and improved HIV programs, the number of new global HIV infections declined 19% over the past decade. However, this progress is fragile and unevenly distributed. HIV incidence is still increasing in some countries and regions, and too many new infections are occurring, 2.6 million in 2009 alone, contributing to the current global incidence of 33.3 million.1 New infections continue to outpace the number of people placed on treatment, and the efficacy of the treatments is hampered by the emergence of drug-resistant viral strains and severe drug-drug interactions. Therefore, novel potent antiretroviral agents with different targets and acceptable prices are still urgently needed. Two lupine-type triterpenes betulin and betulinic acid (BA), which are readily available from the birch tree in large quantity, exhibit diverse pharmacological activities, including anti-HIV, anti-cancer, and anti-inflammatory activities.2 Among the BA/betulin derivatives, bevirimat [3-O-(3′,3′-dimethylsuccinyl)betulinic acid, 14] was found to exhibit remarkable anti-HIV-1 activity against primary and drug-resistant HIV-1 isolates,3, 4 representing a unique first in a class of anti-HIV compounds termed Maturation Inhibitors (MIs).4, 5 Bevirimat has recently succeeded in Phase IIb clinical trials.6–9 In our prior study, AZT (3′-azido-3′-deoxythymidine), a clinically used nucleoside reverse transcriptase inhibitor (NRTI), was conjugated with 3-O-(3′,3′-dimethylsuccinyl)betulin at its C-28 position using different linkers. The goal was to provide multi-target therapeutics in one molecule in order to reduce the risk of drug-drug interaction, which can occur from mixing monotherapies,.10 The conjugates were formed via an ester bond, which was meant to subsequently be hydrolyzed inside the cells and release two different chemical entities exerting two pharmacological functions, anti-Maturation and anti-reverse transcriptase. However, one potential drawback of this design is that the hydroxyl group of AZT, which needs to undergo phosphorylation inside host cells to become active, forms the linker bond with the betulin derivatives. Consequently, the inhibitory ability of AZT is highly dependent on the ability of the conjugate to dissociate. In order to improve this issue, we investigated another strategy to link AZT with betulin and BA via the azido group of AZT by using click chemistry. Click chemistry as introduced by K. Barry Sharpless is a chemical philosophy to mimic nature’s ability to make carbon-heteroatom bonds rather than carbon-carbon bonds.11 Conjugation of AZT with betulin and BA by this methodology has the following potential benefits. 1) Click chemistry is designed to link the azido group of AZT with an alkyne group on betulin/BA derivatives, leaving the hydroxyl group of AZT free to be phosphorylated. 2) The linking triazole group is physiologically stable in cells. Thus, the new conjugated molecule will not be degraded inside the cells, which should reduce the potential drug-drug interactions. 3) In addition, the triazole linkage formed by click chemistry may also offer extra interaction with virus proteins. Based on this rationale, the present study reports the synthesis and anti-HIV activity of the newly designed AZT-betulin and AZT-BA conjugates. The synthetic route to compounds conjugated at the C-3 position of betulin is outlined in Scheme 1. The C-28 hydroxyl of betulin was first protected by reaction with tert-butyldimethylsilyl chloride (TBSCl) to yield the silyl ether 1. Prop-2-ynyl groups were then introduced at the C-3 position as either an ether (2) or carbonate ester (3). Compounds 2 and 3 were then reacted with the azido group of AZT in the presence of Cu and CuSO4·5H2O to furnish final compounds 8 and 9 in quantitative yields. Analogous final compounds 10 and 11 were obtained by the same click reaction of AZT with the C-28 de-protected betulin derivatives 4 and 5. Oxidation of the C-28 hydroxyl of 4 with Jones reagent yielded 6, which was also reacted with AZT to yield 12, an AZT-BA conjugate. Finally, a 3′,3′-dimethylsuccinyl ester was introduced at the C-28 position of 4 to yield compound 7, which was converted by click chemistry to the conjugate 13. Scheme 2 depicts the synthesis of AZT-bevirimat conjugates. A prop-2-ynyl ester moiety was added to the C-28 position of bevirimat (14) to furnish 15, followed by click reaction of 15 with AZT to yield final compound 16. Compared with the previous yields (42.7–87.3%) for conjugating AZT with betulin derivatives via an ester bond,10 the click reactions of AZT with betulin/BA derivatives were achieved quantitatively, which is a significant advantage in the last step of synthesizing the target compounds. In addition, the reaction time was shortened significantly to 30 min by using microwave conditions at 120 °C (followed by dilution with EtOAc, washing with NaHCO3 and brine, and chromatography), rather than the prior overnight esterification reaction. Therefore, the click reaction provides a much more productive and rapid approach to obtain the final products of AZT-betulin/BA conjugates. Scheme 1 AZT conjugation at C-3 position Scheme 2 AZT conjugation at C-28 position The anti-HIV activity data of all new compounds are summarized in Table 1. Among the tested compounds, conjugates 8 and 13 with AZT linked through the C-3 side chain of betulin/BA showed moderate antiviral activity with EC50 values of 0.19 and 0.35 µM, respectively. The C-3 ether bond (8) was favored for activity compared with the C-3 carbonate ester bond (corresponding conjugate 9 was inactive). Conjugates with a free C-28 hydroxyl (10 and 11) or carboxylic acid group (12) showed no inhibitory activity, compared with conjugates with a C-28 TBS ether (8) or dimethylsuccinyl ester (13). Between the two active conjugates, the smaller C-28 TBS side chain in 8 was favored compared with the longer dimethylsuccinyl side chain in 13. Overall, in this limited data set, when AZT and betulin/BA are conjugated at the C-3 position, a shorter distance between AZT-betulin/BA and the presence of a small extra side chain at C-28 are important for the conjugates’ antiviral activity. Table 1 Anti-HIV data against HIV-1NL4–3 infected MT-4 cells. The non-conjugated 15 with a 3-O-3′,3′-dimethylsuccinyl side chain at C-3 and propynyl ester moiety at C-28 showed potent anti-HIV activity with an EC50 of 0.067 µM and a selectivity index (SI, ratio of cytotoxic/anti-viral activity) of 226. The AZT-bevirimat conjugate 16 also exhibited anti-HIV activity with an EC50 of 0.10 µM and a SI of 101. Thus, these two compounds and AZT (EC50: 0.10 µM) showed comparable activity in our assay system. As a pioneer compound, conjugate 16 demonstrates that a click reaction can be used easily with a large natural product (e.g. BA), which contains a terminal alkyne moiety, to form conjugates. The potent anti-HIV activity of compounds 15 and 16 proves that the incorporation of a C-28 side chain in bevirimat may result in retained or even increased antiviral activity. We are currently investigating synthesis and antiviral evaluation of additional AZT-bevirimat conjugates with different sizes/lengths of linkers between the C-28 carboxylic acid and the triazole moiety formed by click reaction with AZT. In conclusion, conjugation via triazole linkage offers a new direction of modification of anti-HIV triterpenes. Click chemistry provides an easy and productive way for linking two molecules, even when one of them is a large natural product. Preliminary results indicated that AZT-betulin/BA conjugates with proper substitutions at the C-3 and C-28 positions showed potent antiviral activity comparable to bevirimat and AZT. Mechanistic studies are currently ongoing.
-
anti aids agents 81 design synthesis and structure activity relationship study of betulinic acid and moronic acid derivatives as potent hiv Maturation Inhibitors
Journal of Medicinal Chemistry, 2010Co-Authors: Keduo Qian, Chin Ho Chen, Li Huang, Susan L MorrisnatschkeAbstract:In our continuing study of triterpene derivatives as potent anti-HIV agents, different C-3 conformationally restricted betulinic acid (BA, 1) derivatives were designed and synthesized in order to explore the conformational space of the C-3 pharmacophore. 3-O-Monomethylsuccinyl-betulinic acid (MSB) analogues were also designed to better understand the contribution of the C-3′ dimethyl group of bevirimat (2), the first-in-class HIV Maturation inhibitor, which is currently in phase IIb clinical trials. In addition, another triterpene skeleton, moronic acid (MA, 3), was also employed to study the influence of the backbone and the C-3 modification toward the anti-HIV activity of this compound class. This study enabled us to better understand the structure−activity relationships (SAR) of triterpene-derived anti-HIV agents and led to the design and synthesis of compound 12 (EC50: 0.0006 μM), which displayed slightly better activity than 2 as a HIV-1 Maturation inhibitor.
Li Huang - One of the best experts on this subject based on the ideXlab platform.
-
anti aids agents 90 novel c 28 modified bevirimat analogues as potent hiv Maturation Inhibitors
Journal of Medicinal Chemistry, 2012Co-Authors: Keduo Qian, Kuo Hsiung Lee, Chin Ho Chen, Li Huang, Ibrahim D BoriAbstract:In a continuing study of bevirimat (2), the anti-HIV-Maturation clinical trials agent, 28 new betulinic acid (BA, 1) derivatives were designed and synthesized. Among these compounds, 17, with a C-28 MEM ester moiety, and 22, with a C-28 ethyl hexanoate, increased the anti-HIV replication activity compared with 2 by 2-fold while compounds 40, 41, 48, and 49, with C-28 piperazine or piperidine amide substitutions, increased the activity by 3- to 15-fold. The best new compound, 41, exhibited an anti-HIV IC50 of 0.0059 μM compared with 0.087 μM for 2. All of the active compounds showed only antiMaturation effects, as confirmed by TZM-bl assay, in blocking the HIV replication. The results suggest that proper C-28 substitutions can further enhance the antiMaturation activity of 2 without any antientry effects. Thus, 41 may serve as a promising new lead for development of anti-AIDS clinical trial candidates.
-
anti aids agents 81 design synthesis and structure activity relationship study of betulinic acid and moronic acid derivatives as potent hiv Maturation Inhibitors
Journal of Medicinal Chemistry, 2010Co-Authors: Keduo Qian, Chin Ho Chen, Li Huang, Susan L MorrisnatschkeAbstract:In our continuing study of triterpene derivatives as potent anti-HIV agents, different C-3 conformationally restricted betulinic acid (BA, 1) derivatives were designed and synthesized in order to explore the conformational space of the C-3 pharmacophore. 3-O-Monomethylsuccinyl-betulinic acid (MSB) analogues were also designed to better understand the contribution of the C-3′ dimethyl group of bevirimat (2), the first-in-class HIV Maturation inhibitor, which is currently in phase IIb clinical trials. In addition, another triterpene skeleton, moronic acid (MA, 3), was also employed to study the influence of the backbone and the C-3 modification toward the anti-HIV activity of this compound class. This study enabled us to better understand the structure−activity relationships (SAR) of triterpene-derived anti-HIV agents and led to the design and synthesis of compound 12 (EC50: 0.0006 μM), which displayed slightly better activity than 2 as a HIV-1 Maturation inhibitor.